Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Covered in this story
Call it yourself
No calls on $RZLT yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Rezolute Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.